APLLTDAlembic Pharmaceuticals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on APLLTD — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Profit growth: 29.2% YoY
- • Debt/Equity: 0.25
- • Promoter holding: 70.7%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Supertrend: bullish
Bull case
- • Profit growth: 29.2% YoY
- • Debt/Equity: 0.25
- • Promoter holding: 70.7%
- • Price vs SMA200: above
Bear case
- • Revenue growth: 4.4% YoY
- • MACD: bearish
- • Price vs EMA21: below
- • 1-month return: -2.4%
Key risks
- • Revenue growth: 4.4% YoY
- • MACD: bearish
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹23.31). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.